Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

NCT02200614 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1509

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer Non-Metastatic
Castration-Resistant

Interventions

DRUG: Darolutamide (Nubeqa, BAY1841788)
DRUG: Placebo

Sponsor

Bayer

Collaborators

[object Object]